RLMD Relmada Therapeutics
Price Chart
Executive Summary
Relmada Therapeutics announced a $160 million PIPE financing through the sale of common stock and pre-funded warrants, with proceeds intended for R&D and general corporate purposes. The offering includes significant participation from major healthcare investors and is expected to close March 11, 2026, subject to customary conditions.
Key Financial Metrics
Actionable Insight
Monitor for the filing of the resale registration statement and watch for any insider trading activity or follow-on commentary on clinical development timelines. The influx of cash extends the runway but adds meaningful dilution; assess whether upcoming catalysts justify the expanded share count.
Key Facts
- Relmada raised $160 million in gross proceeds via a PIPE financing.
- The offering includes 29,474,569 shares of common stock at $4.75 per share and pre-funded warrants for 4,210,527 shares at $4.749 per warrant.
- Pre-funded warrants have an exercise price of $0.001 per share.
- Proceeds will fund working capital, R&D advancement, and general corporate purposes.
- Major institutional investors participated, including RA Capital, OrbiMed, Janus Henderson, and Balyasny.
- A registration rights agreement requires Relmada to file a resale registration statement with the SEC.
- Closing expected on or about March 11, 2026, subject to customary conditions.
Financial Impact
$160 million gross proceeds; significant near-term dilution from 33.7 million new shares (approx 14.3% of current shares outstanding assuming 235M prior float)
Risk Factors
- Significant shareholder dilution from issuance of ~33.7 million new shares and pre-funded warrants.
- Resale registration could increase near-term selling pressure as investors may flip shares.
- No guarantee that R&D spending will lead to clinical success or regulatory approval.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3251705 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 13, 2026
27d ago
|
S-3ASR
| $7.42 $7.21 | ▲ +2.83% | ▲ +2.11% | $6.27 (+15.50%) |
|
May 12, 2026
28d ago
|
8-K
| $7.49 $7.03 | ▼ −6.14% | ▼ −4.98% | $6.27 (−16.29%) |
|
Apr 17, 2026
7w ago
|
DEFA14A
| $7.37 $7.03 | ▼ −4.61% | ▼ −5.53% | $6.27 (−14.93%) |
|
Apr 3, 2026
9w ago
|
S-3
| $6.90 $7.38 | ▲ +6.96% | ▲ +2.82% | $6.27 (−9.13%) |
|
Mar 19, 2026
11w ago
|
Press Release
| $6.07 $6.43 | ▲ +5.93% | ▲ +8.08% | $6.27 (+3.29%) |
|
Mar 12, 2026
12w ago
|
Press Release
| $6.15 $6.25 | ▲ +1.63% | ▲ +2.60% | $6.27 (+1.95%) |
|
Mar 9, 2026
13w ago
|
Press Release
| $7.17 $6.18 | ▼ −13.81% | ▼ −12.45% | $6.27 (−12.55%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access